Skip to main content
SpringerLink
Log in

Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent. We assessed six patients with oligodendrogliomas with 1p intact (38%) and 10 patients with 1p loss (62%), who received temozolomide.

Chromosome 1p status was significantly associated with response to treatment using temozolomide. While nine of 10 patients (90%) with 1p loss responded to temozolomide, only two of six patients (33%) with 1p intact benefited from this treatment (p = 0.04). Although the number of patients evaluated was small, there was no association between 1p status and gender, age, and tumor grade. Gender, age, and tumor grade were similarly not correlated with response to chemotherapy.

This report is the first to find that patients harboring oligodendrogliomas with 1p loss are more likely to be sensitive to treatment with temozolomide than those that retain this chromosomal element. Larger prospective trials are needed to confirm these findings; however, temozolomide should be considered in the management of these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reifengerger G, Kros JM, Burger PC, Louis DN, Collins VP: Oligodendroglioma. In: Kleihues P, Cavenee WK (eds) WHO Classification – Tumours of the Nervous System. IARC Press, Lyon, pp 56–61, 2000

    Google Scholar 

  2. Central Brain Tumor Registry of the United States (CBTRUS): 1995 Ref Type: Data File

  3. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35(6): 1018–1034, 1994

    Google Scholar 

  4. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19(1): 15–21, 1986

    Google Scholar 

  5. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428–434, 1992

    Google Scholar 

  6. Zulch KJ: Brain Tumors. Their Biology and Pathology, 3rd edn. Springer Verlag, Heidelberg, Germany, 1986

    Google Scholar 

  7. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23(4): 360–364, 1988

    Google Scholar 

  8. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31(1): 78–82, 1992

    Google Scholar 

  9. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54(1): 91–95, 1995

    Google Scholar 

  10. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64(3): 207–210, 1995

    Google Scholar 

  11. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145(5): 1175–1190, 1994

    Google Scholar 

  12. Chinot O: Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28(Suppl 13): 13–18, 2001

    Google Scholar 

  13. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19): 1473–1479, 1998

    Google Scholar 

  14. Rodriguez LA, Levin VA: Does chemotherapy benefit the patient with a central nervous system glioma? Oncology (Huntingt) 1(9): 29–1, 1987

    Google Scholar 

  15. Cairncross JG, Laperriere NJ: Low-grade glioma. To treat or not to treat? Arch Neurol 46(11): 1238–1239, 1989

    Google Scholar 

  16. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH: Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 65(2): 287–291, 1992

    Google Scholar 

  17. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ: Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3(7): 1093–1100, 1997

    Google Scholar 

  18. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson, J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9): 2762–2771, 1999.

    Google Scholar 

  19. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A(13): 2236–2241, 1996

    Google Scholar 

  20. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A(7): 940–942, 1993

  21. van Den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, et al.: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57(2): 340–342, 2001

    Google Scholar 

  22. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9): 2449–2455, 2001

    Google Scholar 

  23. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, G reenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588–593, 2000

    Google Scholar 

  24. Reifenberger G, Kros J, Burger PC, Louis DN, Collins VP: Anaplastic oligodendroglioma. In: Kleihues P, Cavenee WK (eds) WHO Classification Tumours of the Nervous System. IARC Press, Lyon, pp 62–69, 2000

    Google Scholar 

  25. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE: Clinicopathologic correlations in the oligodendroglioma. Cancer 59(7): 1345–1352, 1987

    Google Scholar 

  26. Chin HW, Hazel JJ, Kim TH, Webster JH: Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45(6): 1458–1466, 1980

    Google Scholar 

  27. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II:Anewgrading system based on morphological and imaging criteria. J Neuro-Oncol 34(1): 61–78, 1997

    Google Scholar 

  28. Kros JM, Pieterman H, van Eden CG, Avezaat CJ: Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34(6): 959–966, 1994

    Google Scholar 

  29. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C: Prognostic factors in oligodendroglioma. Can J Neurol Sci 24(4): 313–319, 1997

    Google Scholar 

  30. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, Macdonald D, Stitt L, Cairncross JG: Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45(4): 923–929, 1999

    Google Scholar 

  31. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II:Anewgrading system based on morphological and imaging criteria. J Neuro-Oncol 34(1): 61–78, 1997

    Google Scholar 

  32. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP: Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 34(1): 37–59, 1997

    Google Scholar 

  33. Shimizu KT, Tran LM, Mark RJ, S elch MT: Management of oligodendrogliomas. Radiology 186: 569–572, 1993

    Google Scholar 

  34. Huang F, Kanno H, Yamamoto I, Lin Y, Kubota Y: Correlation of clinical features and telomerase activity in human gliomas. J Neuro-Oncol 43(2): 137–142, 1999

    Google Scholar 

  35. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljarvi L, Isola J, Haapasalo H: CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neuro-Oncol 41(3): 205–211, 1999

    Google Scholar 

  36. Franzini A, Leocata F, Cajola L, Servello D, Allegranza A, Broggi G: Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. Neurosurgery 35(5): 817–820, 1994

    Google Scholar 

  37. Heegaard S, Sommer HM, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10): 1809–1813, 1995

    Google Scholar 

  38. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78(5): 1107–1113, 1996

    Google Scholar 

  39. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, al Sarraf M: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78(6): 909–914, 1993

    Google Scholar 

  40. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8): 2585–2597, 1993

    Google Scholar 

  41. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12(10): 2013–2021, 1994

    Google Scholar 

  42. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85(4): 602–607, 1996

    Google Scholar 

  43. Olson JD, Riedel E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7): 1442–1448, 2000

    Google Scholar 

  44. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76(5): 741–745, 1992

    Google Scholar 

  45. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3): 636–645, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Ali Chahlavi, Andrew Kanner & Gene Barnett

  2. Department of Hematology/Oncology, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    David Peereboom

  3. Department of Anatomic Pathology, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Susan M. Staugaitis

  4. Department of Biostatistics, Brain Tumor Institute, Cleveland Clinic Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Paul Elson

Authors
  1. Ali Chahlavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Kanner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Peereboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan M. Staugaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Elson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gene Barnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chahlavi, A., Kanner, A., Peereboom, D. et al. Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results. J Neurooncol 61, 267–273 (2003). https://doi.org/10.1023/A:1022580610598

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022580610598

Search

Navigation